Company intelligence / Profile preview

Acambis plc

Cambridge, Cambridgeshire, UK

Ownership: Private
Employees: ~270
Development stage: Other

Overview

Acambis developed the FDA-approved ACAM2000® smallpox vaccine, which is stockpiled by the US government for biodefense. Other programs included advanced clinical candidates targeting Japanese encephalitis, West Nile virus, dengue fever, influenza, C. difficile infection, and herpes simplex. The company was acquired by Sanofi Pasteur in 2008 and its lead products were integrated into Sanofi’s portfolio.

Therapeutic areas: Infectious Diseases
Modalities: Vaccines (live attenuated, inactivated, recombinant viral vector)
Industry: Biotech

Partnerships

Baxter Healthcare (investor/shareholder)Harvard University Office of Technology Development (herpes program licensee)Bavarian Nordic (MVA patent cross-license settlement)Crucell NV (Berna Products sale partner)

Beyond the preview

Go deeper on Acambis plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acambis plc.